Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $700.00 at Truist Financial

Praxis Precision Medicines (NASDAQ:PRAX) had its price objective raised by equities researchers at Truist Financial from $500.00 to $700.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price target suggests a potential upside of 105.88% from the company’s current price.

Other equities analysts have also issued reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of Praxis Precision Medicines in a research note on Monday, December 29th. Chardan Capital raised Praxis Precision Medicines to a “strong-buy” rating in a report on Wednesday, November 19th. Needham & Company LLC upped their target price on Praxis Precision Medicines from $460.00 to $510.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $450.00 target price (up from $300.00) on shares of Praxis Precision Medicines in a research report on Tuesday, December 9th. Finally, Citigroup reiterated a “conviction-buy” rating on shares of Praxis Precision Medicines in a research note on Tuesday, December 30th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Praxis Precision Medicines has an average rating of “Moderate Buy” and a consensus target price of $580.88.

Praxis Precision Medicines Trading Up 2.5%

NASDAQ:PRAX traded up $8.39 during trading hours on Friday, hitting $340.00. 266,515 shares of the company traded hands, compared to its average volume of 531,028. Praxis Precision Medicines has a twelve month low of $26.70 and a twelve month high of $335.75. The firm has a 50-day moving average of $299.27 and a 200 day moving average of $176.28. The stock has a market capitalization of $8.56 billion, a price-to-earnings ratio of -26.24 and a beta of 2.84.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($3.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.00) by ($0.50). Equities research analysts predict that Praxis Precision Medicines will post -10.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC lifted its holdings in shares of Praxis Precision Medicines by 88.3% during the second quarter. Nisa Investment Advisors LLC now owns 629 shares of the company’s stock valued at $26,000 after acquiring an additional 295 shares during the period. CWM LLC increased its position in shares of Praxis Precision Medicines by 877.9% during the 2nd quarter. CWM LLC now owns 753 shares of the company’s stock worth $32,000 after purchasing an additional 676 shares in the last quarter. NBC Securities Inc. bought a new position in Praxis Precision Medicines during the 4th quarter valued at about $38,000. Danske Bank A S bought a new position in Praxis Precision Medicines during the 4th quarter valued at about $59,000. Finally, GAMMA Investing LLC boosted its position in Praxis Precision Medicines by 58.7% in the fourth quarter. GAMMA Investing LLC now owns 238 shares of the company’s stock valued at $70,000 after buying an additional 88 shares in the last quarter. 67.84% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Praxis Precision Medicines

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: Praxis said it submitted two NDAs to the FDA — one for ulixacaltamide in essential tremor (ET) and one for relutrigine for SCN2A/SCN8A developmental and epileptic encephalopathies (DEEs). These filings materially advance commercialization prospects and underpin the company’s long‑term revenue thesis. Praxis Provides Corporate Update and Reports Q4 and Full‑Year 2025 Financial Results
• Positive Sentiment: Guggenheim reiterated a Buy and sharply raised its price target (reported coverage suggests very bullish upside expectations), which supports investor optimism about ulixacaltamide’s market opportunity. Praxis Gains Analyst Confidence With Ulixacaltamide
• Positive Sentiment: Company earnings call materials and previews highlighted solid financials/cash position and corporate updates that investors may interpret as providing runway to support regulatory work and potential launches. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Wells Fargo initiated coverage with an Equal‑Weight rating and a $282 target, a cautious stance that tempers some of the bullish analyst commentary but is not a sell signal. Wells Fargo Cautious on Praxis Precision After Recent Revenue Estimates
• Neutral Sentiment: Market previews and earnings breakdowns circulated ahead of and after the release — useful for investors but largely informational unless guidance or surprises emerge. Q4 2025 Earnings Report Preview Earnings Breakdown: Praxis Q4
• Negative Sentiment: Praxis reported a Q4 EPS miss: ($3.50) vs. consensus ($3.00). That shortfall, and any weaker near‑term revenue or guidance, pressures the stock while the market digests when/if revenue will ramp from product launches. Earnings Report & Conference Call
• Negative Sentiment: Wedbush raised its price target to $130 but kept an Underperform rating — the new PT implies a very large downside relative to the recent share price and may amplify selling from investors focused on near‑term valuation. Wedbush Raises PT to $130 While Maintaining Underperform

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.